Please login to the form below

Not currently logged in


This page shows the latest MINT news and features for those working in and with pharma, biotech and healthcare.

Takeda grows in Turkey with Neutec subsidiary acquisition

Takeda grows in Turkey with Neutec subsidiary acquisition

Along with fellow MINT bloc countries Mexico, Indonesia and Nigeria, Turkey is considered an attractive market for the pharma industry thanks to its increasingly affluent population and long-term growth potential,

Latest news

  • Turkey aims to become ‘global player’ in biopharma Turkey aims to become ‘global player’ in biopharma

    As one of the new MINT block of emerging markets (along with Mexico, Indonesia and Nigeria), the country has attracted quite a lot of investment from pharma multinationals, keen to tap

  • Safety in numbers

    The law calls for serialised codes in a 2D datamatrix format which will be printed on self-adhesive security labels supplied by the Brazilian mint.

  • Survival tactics

    Mundipharma International (MINT) and its independent associated companies are perhaps more like an investor with go-to-market capabilities than a traditional pharmaceutical company. ... MINT realised this and moved quickly to facilitate the acquisition

  • In mint condition

    The potential economic benefit of maintaining a healthy workforce should be considered when valuing health technologies

  • Hospital trust criticised for limiting heart treatment

    It is just one way that the private sector makes a mint out of stupid NHS targets.î.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

  • Deep Dive - MINT: opportunities in ‘frontier’ markets?

    What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. ... In our latest article for Pharmaphorum’s Deep Dive magazine Rachel Howard and Sue Rees investigate what the opportunities may be for pharma

  • Turkey: Identifying the Growth Drivers

    Published in eye for pharma 3 April by Marc Yates. Last year, I concluded my series of articles outlining the challenges and opportunities for pharma in the “MINT” countries, by stating ... Whilst the private sector represents the greatest

  • Is MINT the next BRIC?

    Earlier this year, O’Neill came out of retirement to generate buzz about ‘MINT’ – that’s Mexico, Indonesia, Nigeria and Turkey to the uninitiated – as the next generation ‘ones to watch’ ... We will continue to monitor the MINT market,

  • Exploring MINT: Part 4 - Turkey

    Turkey. Why Turkey? With a population of approximately 75 million, Turkey has the smallest population of all of the ‘MINT’ markets. ... As a result the greatest opportunities for pharma, within the MINT markets, at this stage often lie within the

  • Exploring MINT: Part 3 - Nigeria

    From a healthcare perspective, Nigeria has some parallels with the other MINT markets of Mexico and Indonesia. ... Given the infrastructural, political and fiscal challenges, Nigeria’s potential may also take longer to realise, relative to the other

More from PMHub
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...